Akebia Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $184,844 | $51,870 |
| Inventories | 15,610 | 16,243 |
| Accounts receivable, net | 47,031 | 34,368 |
| Prepaid expenses and other current assets | 5,470 | 11,350 |
| Total current assets | 252,955 | 113,831 |
| Property and equipment, net | 1,222 | 2,200 |
| Operating right-of-use assets | 3,663 | 8,218 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 59,681 | 37,377 |
| Total assets | $376,565 | $220,670 |
| Liabilities and stockholders' equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $21,185 | $15,180 |
| Accrued expenses and other current liabilities | 121,716 | 63,460 |
| Short-term deferred revenue | 2,681 | — |
| Working Capital Fund liability, current portion | 17,356 | 2,274 |
| Total current liabilities | 162,938 | 80,914 |
| Long-term operating lease liabilities | — | 3,547 |
| Long-term debt, net | 48,250 | 38,693 |
| Liability related to settlement royalties, net of current portion | 54,750 | 46,697 |
| Liability related to sale of future royalties, net of current portion | 50,608 | 52,066 |
| Working Capital Fund liability, net of current portion | 22,606 | 38,013 |
| Warrant liability | 2,980 | 5,176 |
| Other long-term liabilities | 1,823 | 4,749 |
| Total liabilities | 343,955 | 269,855 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock: $0.00001 par value; 350,000,000 shares authorized at December 31, 2025 and 2024; 265,424,818 and 224,848,992 shares issued and outstanding at December 31, 2025 and 2024, respectively | 2 | 2 |
| Additional paid-in capital | 1,716,307 | 1,629,167 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,683,705) | (1,678,360) |
| Total stockholders' equity (deficit) | 32,610 | (49,185) |
| Total liabilities and stockholders' equity (deficit) | $376,565 | $220,670 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.